Understanding Testicular Cancer

Testicular Cancer Survival Rates: Key Statistics

Last updated and reviewed on June 28, 2026.

Testicular cancer is one of the great success stories in oncology. When people first hear "cancer," they often expect statistics filled with grim numbers. For testicular cancer, the numbers tell a very different story. It is one of the most curable cancers in all of medicine, with an overall five-year survival rate that exceeds 95 percent across all stages combined. Even for men diagnosed with cancer that has spread to distant organs, the cure rate is over 70 percent with standard treatment. Understanding the statistics and putting them in proper perspective can help make a very frightening diagnosis feel a great deal more manageable.

How Common Is Testicular Cancer?

Testicular cancer is relatively uncommon. According to the American Cancer Society, approximately 9,760 new cases of testicular cancer are expected to be diagnosed in the United States in 2024, and about 500 men are expected to die from the disease. This means that while testicular cancer is serious, it is not among the leading causes of cancer death in men, thanks largely to how effectively it responds to treatment.

Despite its rarity in absolute terms, testicular cancer is the most common cancer in American males between the ages of 15 and 35, which makes it particularly important from a young man's health perspective. The average age at diagnosis is around 33, though it can occur in males of any age, from infants to elderly men.

Rates of testicular cancer have been rising gradually in the United States and in many other Western countries over the past several decades. The reasons for this increase are not well understood. Leading hypotheses include changes in prenatal hormonal exposures, increasing rates of cryptorchidism in developed countries, and environmental or lifestyle factors, though none of these explanations has been definitively proven.

What Is the Survival Rate for Testicular Cancer?

Testicular cancer has some of the highest survival rates of any cancer. The five-year relative survival rate, which compares survival in testicular cancer patients to survival in the general population of the same age and sex, is extraordinary by the standards of oncology.

According to data from the National Cancer Institute's SEER (Surveillance, Epidemiology, and End Results) database, the survival rates by stage of disease at diagnosis are as follows:

These numbers are remarkable. A 99 percent five-year survival rate for localized disease means that virtually all men whose testicular cancer is found before it has spread are alive five years later. Even for men with cancer that has spread to distant organs, the 73 percent five-year survival rate is far better than the survival rates for most other cancers with distant spread.

Important context: These statistics reflect outcomes for patients diagnosed and treated in the recent past. Treatment has continued to evolve, and results today may be at least as good as, or better than, the numbers shown here. Statistics also describe large groups of patients, not what will happen to any individual. Many factors specific to an individual patient, including the type of tumor, the tumor markers, the specific organs affected by spread, and how well the cancer responds to initial treatment, all influence outcomes in ways that statistics cannot fully capture.

Is Testicular Cancer Curable?

Yes. Testicular cancer is curable at all stages, including after it has spread to distant organs. This is one of the most important things to understand about this diagnosis. The development of platinum-based chemotherapy (particularly the BEP regimen, which combines bleomycin, etoposide, and cisplatin) in the 1970s and 1980s transformed testicular cancer from a frequently fatal disease into one of the most curable cancers in medicine. The oncologist who led much of this work, Lawrence Einhorn at Indiana University, is credited with one of the most transformative advances in cancer medicine in the twentieth century.

• For men with Stage I testicular cancer (confined to the testicle), surgery to remove the affected testicle is often all that is needed. Surveillance after surgery is highly effective, and if the cancer does return, subsequent treatment is almost always successful.
• For men with Stage II and Stage III disease, chemotherapy with the BEP regimen cures the large majority of patients, even those with widely spread disease. A small number of patients whose cancer does not respond fully to initial chemotherapy can be treated with high-dose chemotherapy and stem cell transplant, which rescues a meaningful proportion of those patients as well.

Sources

1. American Cancer Society. Key Statistics for Testicular Cancer. https://www.cancer.org/cancer/types/testicular-cancer/about/key-statistics.html
2. National Cancer Institute SEER Database. Cancer Stat Facts: Testicular Cancer. https://seer.cancer.gov/statfacts/html/testis.html
3. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2024. CA: A Cancer Journal for Clinicians. 2024;74(1):12-49. https://pubmed.ncbi.nlm.nih.gov/38230766/
4. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical Treatment of Advanced Testicular Cancer. JAMA. 2008;299(6):672-684. https://pubmed.ncbi.nlm.nih.gov/18270356/
5. Einhorn LH. Treatment of testicular cancer: a new and improved model. Journal of Clinical Oncology. 1990;8(11):1777-1781. https://pubmed.ncbi.nlm.nih.gov/1700077/
6. National Cancer Institute. Testicular Cancer Treatment (PDQ) Patient Version. https://www.cancer.gov/types/testicular/patient/testicular-treatment-pdq